Key result
Evaluation in 2020 linked to ~12% lower full HF medication adherence vs 2018.
Why the study?
Changes in medication adherence over time in heart failure patients using direct serum drug level testing were not well characterized.
Cohort (n=402)
No
Direct adherence monitoring via serum drug levels confirms that adherence to guideline-directed medical therapy in specialized heart failure centers is exceptionally high (81%).
Answers are grounded in this paper and cite their sources.
May warrant closer adherence monitoring during disruptions in HF care; observational cohort leaves open causality and generalizability.
OBJECTIVE: To determine changes in medication adherence in two cohorts of heart failure patients differing by year of data collection and using a direct method of adherence detection - serum drug level testing. METHODS: We added a second cohort of patients to a prospective monocentric registry of chronic heart failure patients (LEVEL-CHF registry). The two cohorts share the same inclusion criteria but differ by the year of enrolment (2018 and 2020). Stable patients with heart failure with reduced ejection fraction were enrolled in a specialized university hospital center. RESULTS: We included 402 records of 366 individual patients, 274 in 2018 and 128 in 2020. 36 patients were enrolled in both cohorts. Of the total 81% of patients were fully adherent, and 19% were non-adherent to a varying degree. Between 2018 and 2020 there was a statistically significant increase in BMI (P=0.047) and fasting glycemia (P=0.009). Patients in the 2020 cohort were less adherent than those in the 2018 cohort (P<0.01). Patients in the two cohorts had similarly severe heart failure and did not substantially differ in NYHA class. There were no statistically significant differences between adherent and non-adherent patients after adjusting for multiple comparisons. CONCLUSIONS: In this comparison, most patients were fully adherent to all their medication and very few were non-adherent to multiple medications. We found no clinically relevant differences between adherent and non-adherent patients. Serum drug level testing is an effective method of adherence testing in clinical practice.
No takes yet. Share an insight, caveat, or question.
Jelínek et al. (2025) conducted a cohort in Heart failure with reduced ejection fraction (n=402). Year of enrollment (2020) vs. Year of enrollment (2018) was evaluated on Full medication adherence measured by serum drug levels (p=<0.01). Patients evaluated in 2020 were less likely to be fully adherent to their prescribed heart failure medications compared to those evaluated in 2018.
Synapse has enriched 10 related papers. Consider them for comparative context: